Nabriva Therapeutics (NASDAQ:NBRV) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, ValuEngine reports.

Several other equities analysts have also commented on the stock. Gabelli upgraded shares of Nabriva Therapeutics from a sell rating to a hold rating and set a $2.00 price target on the stock in a research note on Thursday, May 2nd. Northland Securities set a $13.00 price target on shares of Nabriva Therapeutics and gave the company a buy rating in a research note on Wednesday, May 8th. HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Nabriva Therapeutics in a research note on Thursday, May 9th. Zacks Investment Research lowered shares of Nabriva Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 17th. Finally, BidaskClub lowered shares of Nabriva Therapeutics from a buy rating to a hold rating in a research note on Friday, May 24th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Nabriva Therapeutics presently has a consensus rating of Buy and an average price target of $7.34.

Nabriva Therapeutics stock traded down $0.09 during mid-day trading on Thursday, hitting $2.28. The company had a trading volume of 799,206 shares, compared to its average volume of 417,227. The stock has a market cap of $2.29 billion, a PE ratio of -1.40 and a beta of 2.40. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $3.27. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.55 and a current ratio of 5.55. The business has a fifty day moving average of $2.31.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $0.56 million. Nabriva Therapeutics had a negative net margin of 3,194.72% and a negative return on equity of 119.75%. As a group, equities analysts expect that Nabriva Therapeutics will post -1.14 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in NBRV. Jane Street Group LLC purchased a new position in shares of Nabriva Therapeutics during the fourth quarter worth approximately $29,000. Two Sigma Advisers LP purchased a new position in shares of Nabriva Therapeutics during the fourth quarter worth approximately $37,000. Commonwealth Equity Services LLC grew its position in shares of Nabriva Therapeutics by 30.0% during the second quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 15,000 shares during the last quarter. Fosun International Ltd purchased a new position in shares of Nabriva Therapeutics during the first quarter worth approximately $1,593,000. Finally, FMR LLC grew its position in shares of Nabriva Therapeutics by 514.2% during the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock worth $2,690,000 after acquiring an additional 1,542,700 shares during the last quarter. Institutional investors and hedge funds own 3.02% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Further Reading: Moving Average Convergence Divergence (MACD)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.